Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017.

Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?
El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print].

Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
Cocito F et al. Leuk Lymphoma. 2017 Mar 13:1-2. doi: 10.1080/10428194.2017.1300890. [Epub ahead of print].

Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.
Campo C et al. Hematol Oncol. 2017 Mar 20. doi: 10.1002/hon.2391. [Epub ahead of print].

Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study.
Otrock ZK et al. Transfusion. 2017 Mar 16. doi: 10.1111/trf.14072. [Epub ahead of print].

In-Hospital Mortality and Post-Transplant Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: a Population-Based Study.
Sanchez L et al. Biol Blood Marrow Transplant. 2017 Mar 9. pii: S1083-8791(17)30331-2. doi: 10.1016/j.bbmt.2017.03.012. [Epub ahead of print].

MRONJ risk reduction pathway – 360 degree survey.
Muthukrishnan A et al. Br Dent J. 2017 Mar 10;222(5):386-390. doi: 10.1038/sj.bdj.2017.225.

How I manage the toxicities of myeloma drugs.
Delforge M et al. Blood. 2017 Mar 8. pii: blood-2017-01-725705. doi: 10.1182/blood-2017-01-725705. [Epub ahead of print].

Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
King T et al. Clin J Oncol Nurs. 2017 Apr 1;21(2):240-249. doi: 10.1188/17.CJON.240-249.

Relapsing bullous amyloidosis of the oral mucosa and acquired cutis laxa in a patient with multiple myeloma: a rare triple association.
Gonzalez-Ramos J et al. Clin Exp Dermatol. 2017 Mar 1. doi: 10.1111/ced.13084. [Epub ahead of print].

An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N et al. Curr Hematol Malig Rep. 2017 Feb 27. doi: 10.1007/s11899-017-0370-5. [Epub ahead of print].

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients with Multiple Myeloma.
Mohan M et al. J Bone Miner Res. 2017 Feb 27. doi: 10.1002/jbmr.3111. [Epub ahead of print].

Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.
Dolgikh TY et al. Bull Exp Biol Med. 2017 Feb;162(4):483-487. doi: 10.1007/s10517-017-3645-x. Epub 2017 Feb 27.

Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions.
Saviet BM et al. J Foot Ankle Surg. 2017 Mar – Apr;56(2):357-361. doi: 10.1053/j.jfas.2016.11.020.